Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 133 | 2023 | 5079 | 11.650 |
Why?
|
Antidepressive Agents | 57 | 2022 | 2889 | 5.860 |
Why?
|
Antimanic Agents | 29 | 2021 | 520 | 5.080 |
Why?
|
Antipsychotic Agents | 46 | 2022 | 3060 | 4.280 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 28 | 2022 | 1988 | 3.350 |
Why?
|
Obsessive-Compulsive Disorder | 12 | 2017 | 1489 | 2.750 |
Why?
|
Psychiatric Status Rating Scales | 43 | 2020 | 6013 | 2.410 |
Why?
|
Psychopharmacology | 6 | 2022 | 148 | 2.270 |
Why?
|
Depressive Disorder | 24 | 2020 | 3727 | 2.030 |
Why?
|
Depressive Disorder, Major | 26 | 2020 | 4745 | 2.020 |
Why?
|
Mood Disorders | 11 | 2014 | 1124 | 1.990 |
Why?
|
Lithium Compounds | 8 | 2024 | 225 | 1.890 |
Why?
|
Valproic Acid | 15 | 2021 | 442 | 1.790 |
Why?
|
Psychiatry | 12 | 2022 | 1689 | 1.730 |
Why?
|
Affect | 10 | 2020 | 1480 | 1.640 |
Why?
|
Citalopram | 3 | 2021 | 402 | 1.620 |
Why?
|
Borderline Personality Disorder | 6 | 2015 | 765 | 1.550 |
Why?
|
Anticonvulsants | 23 | 2021 | 1881 | 1.370 |
Why?
|
Psychotropic Drugs | 6 | 2015 | 883 | 1.160 |
Why?
|
Lithium | 14 | 2020 | 596 | 1.150 |
Why?
|
Psychomotor Agitation | 4 | 2019 | 304 | 1.030 |
Why?
|
Piperazines | 7 | 2015 | 2511 | 1.020 |
Why?
|
Risperidone | 9 | 2004 | 379 | 0.950 |
Why?
|
Existentialism | 5 | 2018 | 39 | 0.930 |
Why?
|
Benzodiazepines | 8 | 2015 | 1130 | 0.920 |
Why?
|
Thiazoles | 5 | 2015 | 1510 | 0.920 |
Why?
|
Antidepressive Agents, Second-Generation | 5 | 2021 | 489 | 0.910 |
Why?
|
Drug Therapy, Combination | 33 | 2021 | 6293 | 0.880 |
Why?
|
Psychopathology | 2 | 2019 | 429 | 0.870 |
Why?
|
Lithium Carbonate | 7 | 2010 | 179 | 0.860 |
Why?
|
Psychotherapy | 9 | 2015 | 1640 | 0.840 |
Why?
|
Triazines | 5 | 2014 | 310 | 0.830 |
Why?
|
Mental Disorders | 13 | 2020 | 6803 | 0.820 |
Why?
|
International Classification of Diseases | 5 | 2014 | 892 | 0.770 |
Why?
|
Clomipramine | 2 | 2017 | 54 | 0.710 |
Why?
|
Randomized Controlled Trials as Topic | 17 | 2024 | 10146 | 0.710 |
Why?
|
Carbamazepine | 5 | 2014 | 224 | 0.680 |
Why?
|
Psychological Theory | 2 | 2012 | 175 | 0.670 |
Why?
|
Cyclohexanecarboxylic Acids | 4 | 2001 | 140 | 0.670 |
Why?
|
Humans | 191 | 2024 | 758406 | 0.660 |
Why?
|
Psychotic Disorders | 12 | 2020 | 3193 | 0.660 |
Why?
|
Amines | 4 | 2001 | 281 | 0.630 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2023 | 3701 | 0.620 |
Why?
|
Comorbidity | 18 | 2015 | 10495 | 0.610 |
Why?
|
Awareness | 7 | 2012 | 644 | 0.600 |
Why?
|
Galantamine | 2 | 2009 | 33 | 0.590 |
Why?
|
Advisory Committees | 5 | 2013 | 785 | 0.580 |
Why?
|
Basal Ganglia Diseases | 5 | 2006 | 144 | 0.570 |
Why?
|
Treatment Outcome | 59 | 2021 | 64378 | 0.570 |
Why?
|
Suicide | 5 | 2024 | 1599 | 0.560 |
Why?
|
Diagnostic Errors | 6 | 2011 | 1263 | 0.560 |
Why?
|
Isoxazoles | 3 | 2007 | 230 | 0.550 |
Why?
|
Sertraline | 2 | 2014 | 208 | 0.530 |
Why?
|
Pirenzepine | 3 | 2000 | 116 | 0.520 |
Why?
|
Acetates | 4 | 2001 | 321 | 0.510 |
Why?
|
Temperament | 2 | 2023 | 295 | 0.510 |
Why?
|
Depression | 8 | 2021 | 8057 | 0.510 |
Why?
|
Carcinogenicity Tests | 1 | 2015 | 38 | 0.510 |
Why?
|
Meta-Analysis as Topic | 3 | 2024 | 1373 | 0.490 |
Why?
|
gamma-Aminobutyric Acid | 5 | 2001 | 1132 | 0.480 |
Why?
|
Quinolones | 2 | 2008 | 377 | 0.480 |
Why?
|
Depression, Postpartum | 2 | 2017 | 345 | 0.460 |
Why?
|
Research Design | 12 | 2020 | 6157 | 0.450 |
Why?
|
Adult | 79 | 2023 | 219935 | 0.440 |
Why?
|
Terminology as Topic | 4 | 2017 | 1533 | 0.440 |
Why?
|
Double-Blind Method | 15 | 2021 | 12262 | 0.440 |
Why?
|
Emergency Services, Psychiatric | 2 | 2006 | 67 | 0.430 |
Why?
|
Trace Elements | 1 | 2014 | 196 | 0.420 |
Why?
|
Behavioral Symptoms | 1 | 2014 | 186 | 0.400 |
Why?
|
Dibenzothiazepines | 3 | 2001 | 102 | 0.400 |
Why?
|
Antidepressive Agents, Tricyclic | 3 | 2007 | 431 | 0.390 |
Why?
|
Clozapine | 4 | 2000 | 506 | 0.390 |
Why?
|
Acute Disease | 12 | 2021 | 7225 | 0.380 |
Why?
|
Dyskinesia, Drug-Induced | 2 | 2002 | 165 | 0.380 |
Why?
|
Affective Symptoms | 2 | 2011 | 416 | 0.380 |
Why?
|
Drug Prescriptions | 2 | 2014 | 1668 | 0.370 |
Why?
|
Drug Administration Schedule | 12 | 2021 | 4839 | 0.370 |
Why?
|
Neuropsychological Tests | 5 | 2018 | 7021 | 0.370 |
Why?
|
Male | 83 | 2021 | 358747 | 0.370 |
Why?
|
Fructose | 3 | 2001 | 287 | 0.360 |
Why?
|
Lithium Chloride | 1 | 2010 | 82 | 0.360 |
Why?
|
Second Messenger Systems | 2 | 2022 | 202 | 0.350 |
Why?
|
Female | 83 | 2021 | 390323 | 0.350 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1335 | 0.340 |
Why?
|
Diagnosis, Differential | 15 | 2017 | 12951 | 0.340 |
Why?
|
Evidence-Based Medicine | 3 | 2011 | 3671 | 0.330 |
Why?
|
Substance-Related Disorders | 4 | 2013 | 4402 | 0.320 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 324 | 0.320 |
Why?
|
Publication Bias | 1 | 2009 | 161 | 0.320 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.310 |
Why?
|
Bibliometrics | 1 | 2012 | 349 | 0.310 |
Why?
|
Nootropic Agents | 1 | 2009 | 157 | 0.300 |
Why?
|
Cyclothymic Disorder | 2 | 2023 | 42 | 0.300 |
Why?
|
Middle Aged | 50 | 2021 | 219568 | 0.300 |
Why?
|
Societies, Medical | 3 | 2009 | 3891 | 0.290 |
Why?
|
Neuroprotective Agents | 1 | 2014 | 955 | 0.290 |
Why?
|
Recurrence | 11 | 2015 | 8426 | 0.290 |
Why?
|
Central Nervous System Stimulants | 3 | 2015 | 1176 | 0.280 |
Why?
|
Philosophy, Medical | 1 | 2007 | 79 | 0.280 |
Why?
|
Publishing | 2 | 2012 | 833 | 0.280 |
Why?
|
Jaundice, Neonatal | 1 | 2007 | 71 | 0.270 |
Why?
|
Placebo Effect | 2 | 2021 | 518 | 0.270 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1659 | 0.270 |
Why?
|
Pharmacogenetics | 1 | 2010 | 675 | 0.270 |
Why?
|
Peer Review, Research | 1 | 2009 | 340 | 0.260 |
Why?
|
Secondary Prevention | 7 | 2011 | 1474 | 0.260 |
Why?
|
Time Perception | 1 | 2006 | 87 | 0.260 |
Why?
|
Observation | 2 | 2006 | 311 | 0.250 |
Why?
|
Prevalence | 9 | 2023 | 15651 | 0.250 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 15225 | 0.250 |
Why?
|
Cognition Disorders | 3 | 2009 | 3975 | 0.250 |
Why?
|
Psychoanalytic Therapy | 2 | 2004 | 228 | 0.240 |
Why?
|
Internal Medicine | 1 | 2012 | 1048 | 0.240 |
Why?
|
Biomedical Research | 2 | 2012 | 3418 | 0.230 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 238 | 0.230 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39059 | 0.220 |
Why?
|
Severity of Illness Index | 14 | 2019 | 15785 | 0.220 |
Why?
|
History, 20th Century | 5 | 2017 | 2772 | 0.210 |
Why?
|
Disease Management | 1 | 2014 | 2500 | 0.210 |
Why?
|
Cultural Diversity | 1 | 2007 | 365 | 0.210 |
Why?
|
Personality Inventory | 3 | 2023 | 1018 | 0.210 |
Why?
|
Age of Onset | 6 | 2014 | 3298 | 0.210 |
Why?
|
Irritable Mood | 4 | 2014 | 194 | 0.200 |
Why?
|
Placebos | 4 | 2020 | 1661 | 0.190 |
Why?
|
Adolescent | 18 | 2021 | 87892 | 0.190 |
Why?
|
Poverty | 1 | 2013 | 2692 | 0.190 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2001 | 36 | 0.180 |
Why?
|
Paroxetine | 2 | 1998 | 182 | 0.180 |
Why?
|
Urinary Tract Infections | 1 | 2007 | 812 | 0.180 |
Why?
|
Akathisia, Drug-Induced | 3 | 2008 | 67 | 0.170 |
Why?
|
Ambulatory Care | 8 | 2008 | 2768 | 0.170 |
Why?
|
Aftercare | 1 | 2006 | 910 | 0.170 |
Why?
|
Young Adult | 10 | 2021 | 58808 | 0.170 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 414 | 0.170 |
Why?
|
Dementia | 1 | 2014 | 2650 | 0.170 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2013 | 303 | 0.170 |
Why?
|
Kindling, Neurologic | 1 | 1999 | 24 | 0.170 |
Why?
|
Thioridazine | 1 | 1998 | 33 | 0.160 |
Why?
|
Community Mental Health Services | 3 | 2011 | 392 | 0.160 |
Why?
|
Polypharmacy | 1 | 2021 | 305 | 0.160 |
Why?
|
Serotonin Antagonists | 1 | 1999 | 144 | 0.150 |
Why?
|
Nortriptyline | 1 | 1998 | 79 | 0.150 |
Why?
|
Long-Term Care | 3 | 2008 | 631 | 0.150 |
Why?
|
Reproducibility of Results | 7 | 2020 | 20055 | 0.150 |
Why?
|
Primary Health Care | 2 | 2020 | 4652 | 0.150 |
Why?
|
Seasonal Affective Disorder | 1 | 1997 | 49 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2008 | 10748 | 0.150 |
Why?
|
Medical Records | 4 | 2006 | 1406 | 0.150 |
Why?
|
Fluvoxamine | 1 | 2017 | 78 | 0.150 |
Why?
|
Humanism | 1 | 2018 | 86 | 0.140 |
Why?
|
Personality | 2 | 2012 | 552 | 0.140 |
Why?
|
Ecosystem | 1 | 2021 | 487 | 0.140 |
Why?
|
Endpoint Determination | 2 | 2011 | 590 | 0.140 |
Why?
|
Mental Health Services | 2 | 2008 | 1718 | 0.140 |
Why?
|
Time Factors | 6 | 2020 | 39872 | 0.130 |
Why?
|
Mass Screening | 3 | 2020 | 5427 | 0.130 |
Why?
|
Electric Injuries | 1 | 1995 | 24 | 0.130 |
Why?
|
Adaptive Immunity | 1 | 2020 | 726 | 0.130 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 999 | 0.120 |
Why?
|
Retrospective Studies | 21 | 2014 | 80168 | 0.120 |
Why?
|
Emotions | 1 | 2006 | 2734 | 0.120 |
Why?
|
Paresthesia | 1 | 1995 | 162 | 0.120 |
Why?
|
Attitude to Health | 3 | 2010 | 2026 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1044 | 0.120 |
Why?
|
GTP-Binding Proteins | 1 | 1999 | 950 | 0.120 |
Why?
|
Psychometrics | 3 | 2018 | 3052 | 0.120 |
Why?
|
South America | 1 | 2014 | 180 | 0.110 |
Why?
|
ROC Curve | 3 | 2018 | 3563 | 0.110 |
Why?
|
Nausea | 2 | 2008 | 677 | 0.110 |
Why?
|
Cross-Sectional Studies | 5 | 2020 | 25956 | 0.110 |
Why?
|
Regression Analysis | 4 | 2008 | 6354 | 0.110 |
Why?
|
Prospective Studies | 9 | 2013 | 54137 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2008 | 7378 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2858 | 0.110 |
Why?
|
Anti-Anxiety Agents | 1 | 2015 | 397 | 0.100 |
Why?
|
Asia | 1 | 2014 | 616 | 0.100 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14641 | 0.100 |
Why?
|
Tunisia | 1 | 2012 | 36 | 0.100 |
Why?
|
History, Medieval | 1 | 2012 | 62 | 0.100 |
Why?
|
Edema | 1 | 1996 | 768 | 0.100 |
Why?
|
Epidemiologic Studies | 2 | 2014 | 670 | 0.100 |
Why?
|
Iraq | 1 | 2012 | 94 | 0.100 |
Why?
|
Drug Utilization | 3 | 2009 | 1187 | 0.100 |
Why?
|
Pilot Projects | 4 | 2009 | 8553 | 0.100 |
Why?
|
Europe | 2 | 2014 | 3420 | 0.100 |
Why?
|
Observer Variation | 1 | 2018 | 2600 | 0.100 |
Why?
|
Behavioral Research | 1 | 2011 | 52 | 0.090 |
Why?
|
Glucocorticoids | 1 | 2020 | 2144 | 0.090 |
Why?
|
Cholesterol | 1 | 2000 | 2902 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1573 | 0.090 |
Why?
|
Aged | 15 | 2020 | 168218 | 0.090 |
Why?
|
MEDLINE | 1 | 2010 | 119 | 0.090 |
Why?
|
Concept Formation | 1 | 2011 | 160 | 0.090 |
Why?
|
North America | 1 | 2014 | 1276 | 0.090 |
Why?
|
Syndrome | 2 | 2009 | 3262 | 0.090 |
Why?
|
Sex Distribution | 2 | 2007 | 2284 | 0.090 |
Why?
|
Interview, Psychological | 1 | 2013 | 809 | 0.090 |
Why?
|
Triazoles | 1 | 1995 | 902 | 0.090 |
Why?
|
Hospitalization | 6 | 2013 | 10652 | 0.090 |
Why?
|
Weight Gain | 3 | 2006 | 2346 | 0.090 |
Why?
|
Students | 1 | 2020 | 1734 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2020 | 1406 | 0.080 |
Why?
|
Cognition | 2 | 2004 | 6953 | 0.080 |
Why?
|
Cross-Over Studies | 1 | 2015 | 2048 | 0.080 |
Why?
|
Age Factors | 4 | 2015 | 18358 | 0.080 |
Why?
|
Motivation | 1 | 1999 | 1996 | 0.080 |
Why?
|
United States | 6 | 2020 | 72136 | 0.080 |
Why?
|
Anxiety Disorders | 1 | 2000 | 2714 | 0.080 |
Why?
|
Schizophrenic Psychology | 1 | 1995 | 1646 | 0.080 |
Why?
|
Self Concept | 2 | 2006 | 1041 | 0.080 |
Why?
|
Wounds and Injuries | 1 | 2020 | 2476 | 0.070 |
Why?
|
Tranylcypromine | 1 | 2007 | 30 | 0.070 |
Why?
|
Greece | 1 | 2008 | 336 | 0.070 |
Why?
|
Frustration | 1 | 2007 | 22 | 0.070 |
Why?
|
Mianserin | 1 | 2007 | 50 | 0.070 |
Why?
|
Reality Testing | 1 | 2006 | 24 | 0.070 |
Why?
|
Biological Psychiatry | 1 | 2007 | 26 | 0.070 |
Why?
|
Lorazepam | 1 | 2008 | 154 | 0.070 |
Why?
|
Patient Selection | 2 | 2011 | 4244 | 0.070 |
Why?
|
Perceptual Distortion | 1 | 2006 | 36 | 0.070 |
Why?
|
Freedom | 1 | 2007 | 69 | 0.070 |
Why?
|
Cyclohexanols | 1 | 2007 | 126 | 0.070 |
Why?
|
Psychoanalytic Theory | 1 | 2007 | 138 | 0.070 |
Why?
|
Schizophrenia | 2 | 2015 | 6910 | 0.070 |
Why?
|
Models, Psychological | 2 | 2014 | 830 | 0.070 |
Why?
|
Parkinson Disease, Secondary | 1 | 2006 | 122 | 0.060 |
Why?
|
Risk Factors | 8 | 2013 | 73809 | 0.060 |
Why?
|
Empathy | 1 | 2010 | 473 | 0.060 |
Why?
|
Dyskinesias | 1 | 2006 | 79 | 0.060 |
Why?
|
History, 19th Century | 1 | 2008 | 720 | 0.060 |
Why?
|
Spirituality | 1 | 2010 | 428 | 0.060 |
Why?
|
Safety | 1 | 2010 | 1147 | 0.060 |
Why?
|
Child Health Services | 1 | 2011 | 644 | 0.060 |
Why?
|
September 11 Terrorist Attacks | 1 | 2006 | 105 | 0.060 |
Why?
|
Internal-External Control | 1 | 2006 | 359 | 0.060 |
Why?
|
Blood Chemical Analysis | 1 | 2007 | 437 | 0.060 |
Why?
|
Bilirubin | 1 | 2007 | 437 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2004 | 7985 | 0.060 |
Why?
|
Anxiety | 1 | 2020 | 4539 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22029 | 0.060 |
Why?
|
Urinalysis | 1 | 2007 | 368 | 0.060 |
Why?
|
Patient Dropouts | 2 | 2004 | 412 | 0.060 |
Why?
|
Demography | 2 | 2007 | 1651 | 0.060 |
Why?
|
Child | 5 | 2015 | 79818 | 0.060 |
Why?
|
Science | 1 | 2007 | 239 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 961 | 0.060 |
Why?
|
Periodicity | 1 | 2005 | 348 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 22032 | 0.060 |
Why?
|
Attitude to Death | 1 | 2007 | 400 | 0.060 |
Why?
|
Sex Factors | 4 | 2008 | 10504 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5331 | 0.060 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2012 | 6234 | 0.050 |
Why?
|
Vomiting | 1 | 2006 | 651 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3018 | 0.050 |
Why?
|
Task Performance and Analysis | 1 | 2007 | 759 | 0.050 |
Why?
|
Prognosis | 3 | 2011 | 29557 | 0.050 |
Why?
|
Reaction Time | 1 | 2009 | 2075 | 0.050 |
Why?
|
Dystonia | 1 | 2006 | 366 | 0.050 |
Why?
|
Drug Resistance | 1 | 2008 | 1593 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3076 | 0.050 |
Why?
|
Electroconvulsive Therapy | 1 | 2008 | 500 | 0.050 |
Why?
|
Canada | 1 | 2008 | 2111 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3196 | 0.050 |
Why?
|
Resilience, Psychological | 1 | 2010 | 772 | 0.050 |
Why?
|
Appointments and Schedules | 1 | 2006 | 441 | 0.050 |
Why?
|
Disclosure | 1 | 2007 | 738 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2467 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2007 | 960 | 0.050 |
Why?
|
Impulsive Behavior | 1 | 2003 | 346 | 0.050 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2003 | 306 | 0.050 |
Why?
|
Haloperidol | 1 | 2002 | 388 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2010 | 14490 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2002 | 367 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2001 | 186 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8611 | 0.040 |
Why?
|
India | 1 | 2007 | 2329 | 0.040 |
Why?
|
Switzerland | 1 | 2001 | 323 | 0.040 |
Why?
|
Survival Analysis | 2 | 2010 | 10112 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4284 | 0.040 |
Why?
|
Public Health | 1 | 2013 | 2658 | 0.040 |
Why?
|
Professional-Patient Relations | 1 | 2005 | 727 | 0.040 |
Why?
|
Memory | 1 | 2009 | 2179 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 1999 | 87 | 0.040 |
Why?
|
Cost of Illness | 1 | 2009 | 1936 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 384 | 0.040 |
Why?
|
Dyslipidemias | 1 | 2006 | 867 | 0.040 |
Why?
|
Risk Assessment | 2 | 2011 | 23884 | 0.040 |
Why?
|
Cohort Studies | 4 | 2007 | 41256 | 0.040 |
Why?
|
Virginia | 1 | 1998 | 117 | 0.040 |
Why?
|
Defense Mechanisms | 1 | 1999 | 180 | 0.040 |
Why?
|
Fluoxetine | 1 | 2002 | 733 | 0.040 |
Why?
|
Outpatients | 1 | 2006 | 1591 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13276 | 0.040 |
Why?
|
Personality Assessment | 1 | 2000 | 650 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2000 | 352 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2006 | 2322 | 0.040 |
Why?
|
Remote Consultation | 1 | 2020 | 234 | 0.040 |
Why?
|
Delusions | 1 | 2000 | 298 | 0.040 |
Why?
|
Culture | 2 | 2008 | 624 | 0.040 |
Why?
|
Videotape Recording | 1 | 1998 | 337 | 0.040 |
Why?
|
Hallucinations | 1 | 2000 | 366 | 0.040 |
Why?
|
Chronic Disease | 1 | 2012 | 9267 | 0.030 |
Why?
|
Research | 1 | 2005 | 1976 | 0.030 |
Why?
|
Acetylcholine | 1 | 1999 | 628 | 0.030 |
Why?
|
Pedigree | 1 | 2004 | 4578 | 0.030 |
Why?
|
Public Sector | 1 | 1998 | 265 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2020 | 868 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16534 | 0.030 |
Why?
|
Hostility | 1 | 1996 | 183 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8530 | 0.030 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2006 | 4560 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2751 | 0.030 |
Why?
|
Commitment of Mentally Ill | 1 | 1995 | 93 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2006 | 2567 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1998 | 1539 | 0.030 |
Why?
|
Phototherapy | 1 | 1997 | 368 | 0.030 |
Why?
|
Developing Countries | 1 | 2007 | 2866 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1999 | 1199 | 0.030 |
Why?
|
Anger | 1 | 1996 | 401 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 2690 | 0.030 |
Why?
|
Health Status | 2 | 2004 | 4071 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2307 | 0.030 |
Why?
|
Patient Readmission | 2 | 1998 | 3261 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1542 | 0.030 |
Why?
|
Massachusetts | 1 | 2006 | 8823 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2006 | 3586 | 0.030 |
Why?
|
Patient Discharge | 1 | 2006 | 3433 | 0.030 |
Why?
|
Cost Savings | 1 | 1998 | 918 | 0.030 |
Why?
|
Family | 1 | 2003 | 3188 | 0.030 |
Why?
|
Hospitals, Psychiatric | 1 | 1994 | 320 | 0.030 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1996 | 388 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18119 | 0.030 |
Why?
|
Data Collection | 1 | 2001 | 3322 | 0.030 |
Why?
|
Consensus | 2 | 2013 | 3099 | 0.020 |
Why?
|
Aggression | 1 | 1996 | 745 | 0.020 |
Why?
|
Cell Communication | 1 | 1999 | 1651 | 0.020 |
Why?
|
Risk | 1 | 2003 | 9599 | 0.020 |
Why?
|
Genetic Markers | 1 | 1998 | 2608 | 0.020 |
Why?
|
Animals | 2 | 2015 | 167768 | 0.020 |
Why?
|
Registries | 1 | 2007 | 8175 | 0.020 |
Why?
|
Mental Recall | 1 | 1996 | 1208 | 0.020 |
Why?
|
Weight Loss | 1 | 2001 | 2671 | 0.020 |
Why?
|
Visual Perception | 1 | 1998 | 1374 | 0.020 |
Why?
|
Delphi Technique | 1 | 2013 | 829 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1996 | 1419 | 0.020 |
Why?
|
Body Weight | 1 | 2000 | 4603 | 0.020 |
Why?
|
Synapses | 1 | 1999 | 1757 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8297 | 0.020 |
Why?
|
Patient Admission | 1 | 1995 | 1372 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2006 | 5816 | 0.020 |
Why?
|
Life Change Events | 2 | 2006 | 953 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 26183 | 0.020 |
Why?
|
Iran | 1 | 2009 | 737 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2005 | 150 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1998 | 5484 | 0.020 |
Why?
|
Pain | 1 | 2020 | 5065 | 0.020 |
Why?
|
Patient Compliance | 1 | 1994 | 2685 | 0.010 |
Why?
|
Morbidity | 1 | 2009 | 1754 | 0.010 |
Why?
|
Stress, Psychological | 1 | 1999 | 4455 | 0.010 |
Why?
|
Mass Media | 1 | 2006 | 301 | 0.010 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2002 | 109 | 0.010 |
Why?
|
Body Mass Index | 1 | 2000 | 12876 | 0.010 |
Why?
|
Antiparkinson Agents | 1 | 2002 | 183 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1386 | 0.010 |
Why?
|
Length of Stay | 1 | 1994 | 6439 | 0.010 |
Why?
|
Suicide, Attempted | 1 | 2009 | 1383 | 0.010 |
Why?
|
Child, Preschool | 1 | 2003 | 42062 | 0.010 |
Why?
|
Benzothiazoles | 1 | 2000 | 246 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13961 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2002 | 429 | 0.010 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2008 | 1079 | 0.010 |
Why?
|
Alzheimer Disease | 1 | 1999 | 8544 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6493 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7818 | 0.010 |
Why?
|
Propranolol | 1 | 1996 | 489 | 0.010 |
Why?
|
Odds Ratio | 1 | 2005 | 9650 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2007 | 12440 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1996 | 914 | 0.010 |
Why?
|